SHERP

Long-term protection against hepatitis B in pediatric liver recipients can be achieved effectively with vaccination after transplantation

Cited 0 time in webofscience Cited 29 time in scopus
Authors
Kwon, Choon Hyuck David; Suh, Kyung-Suk; Yi, Nam-Joon; Chang, Seong-Hwan; Cho, Yong Beom; Cho, Jai-Young; Lee, Hoan Jong; Seo, Jeong Kee; Lee, Kuhn Uk
Issue Date
2006-05-23
Publisher
Blackwell Publishing
Citation
Pediatr Transplant. 2006 Jun;10(4):479-86
Keywords
CadaverFemaleFollow-Up StudiesHepatitis B/blood/*prevention & controlHepatitis B Antibodies/analysisHepatitis B Core Antigens/analysisHepatitis B Vaccines/*therapeutic useHumansImmunization, Secondary/statistics & numerical dataImmunoglobulins/therapeutic useInfant*Liver TransplantationLiving Donors/statistics & numerical dataMaleProspective StudiesRecombinant Proteins/therapeutic useTime FactorsTreatment Outcome*Vaccination
Abstract
Liver recipients who have antibodies to hepatitis B core antigen (anti-HBc) or received an anti-HBc positive liver graft are at risk of acquiring de novo hepatitis B infection so a life long prophylaxis is required. A post-transplant vaccination against hepatitis B virus (HBV) can offer a better alternative than either hepatitis B hyperimmune globulin (HBIG) or lamivudine. This study investigated the course of anti-HBs titer after vaccination and analyzed the factors that influence the response. Between October 1999 and February 2003, 37 pediatric patients were given a post-transplant vaccination when an anti-HBc positive graft was used, the recipient was anti-HBc positive, or when anti-HBs titer was below 20 IU/L irrespective of the serological status. Thirty-three patients responded to the vaccine and did not require further HBIG injections at a mean follow up of 33.6 months. Fifteen patients were good responder and only needed a single set of vaccines, and 18 were poor responder needing additional boosters. Two patients developed de novo hepatitis B infection and two required additional HBIG injections. Preoperative severity of liver disease, serological status of HBV of recipient or donor, use of HBIG or pulse steroid therapy, type of vaccines, and dose or time interval between doses had no influence on response rate. Recipients with a high preoperative anti-HB titer, small graft-recipient weight ratio (GRWR), greater catch up growth, heavier body weight, lower tacrolimus level at the time of vaccination, and longer time interval between transplant or steroid medication and vaccination yielded good response. If well tailored, post-transplant vaccination can be effective and offer patients prophylaxis against de novo hepatitis B infection for a prolonged period of time.
ISSN
1397-3142 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16712607

http://hdl.handle.net/10371/15722
DOI
https://doi.org/10.1111/j.1399-3046.2006.00540.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Surgery (외과학전공)Journal Papers (저널논문_외과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse